Trial · NCT07889245
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
NCT07889245, Phase 2, Not yet recruiting, Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD. Trials, record NCT07889245. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889245
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
- NCT number
- NCT07889245
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 192 participants, estimated
- Lead sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
- Conditions
- sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
- Interventions
- FXR0906 injection, FXR0906 injection, FXR0906 injection, Placebo
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | percent change from baseline at week 24 in fasting triglycerides(TG) | baseline, week 24 | |
| Secondary | percent change from baseline at week 48 in fasting triglycerides(TG) | baseline, week 48 | |
| Secondary | percent change from baseline at week 24 and week 48 in Apolipoprotein (Apo)C-III | baseline, week 24 and week 48 | |
| Secondary | percent change from baseline at week 24 and week 48 in fasting non-high-density lipoprotein cholesterol (non-HDL-C) | baseline, week 24 and week 48 | |
| Secondary | percent change from baseline at week 24 and week 48 in fasting high-density lipoprotein cholesterol (HDL-C) | baseline, week 24 and week 48 | |
| Secondary | percent change from baseline at week 24 and week 48 in fasting Apolipoprotein B (APOB) | baseline, week 24 and week 48 | |
| Secondary | percent change from baseline at week 24 and week 48 in fasting low-density lipoprotein cholesterol (LDL-C) | baseline, week 24 and week 48 | |
| Secondary | number of participants with Treatment-Emergent Adverse Events (TEAEs)T | From first dose of study drug up to Week 60 | |
| Secondary | Changes in Plasma Concentration of FXR0906 | Day1,Day3,Day169 | To investigate changes in plasma concentrations of FXR0906 across different dose groups in participants with sHTG or HTG and ASCVD (confirmed or at increased risk) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889245
GET https://conductscience.org/api/trials/v1/NCT07889245/registered